Delcath Systems Future Growth

Future criteria checks 5/6

Delcath Systems is forecast to grow earnings and revenue by 61.3% and 41.5% per annum respectively while EPS is expected to grow by 65.9% per annum.

Key information

61.3%

Earnings growth rate

65.9%

EPS growth rate

Medical Equipment earnings growth	16.4%
Revenue growth rate	41.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	15 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqCM:DCTH - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	134	46	N/A	N/A	4
12/31/2025	70	-5	N/A	N/A	4
12/31/2024	26	-32	N/A	N/A	4
12/31/2023	2	-48	-31	-31	N/A
9/30/2023	2	-45	-30	-30	N/A
6/30/2023	3	-34	-27	-26	N/A
3/31/2023	3	-37	-23	-23	N/A
12/31/2022	3	-37	-25	-25	N/A
9/30/2022	4	-33	-24	-24	N/A
6/30/2022	4	-32	-24	-23	N/A
3/31/2022	4	-28	-25	-24	N/A
12/31/2021	4	-26	-23	-23	N/A
9/30/2021	2	-27	-22	-22	N/A
6/30/2021	2	-25	-22	-21	N/A
3/31/2021	2	-23	-23	-22	N/A
12/31/2020	2	-24	-24	-23	N/A
9/30/2020	2	-5	-24	-23	N/A
6/30/2020	2	-7	-31	-31	N/A
3/31/2020	2	-9	-26	-26	N/A
12/31/2019	2	-9	-24	-24	N/A
9/30/2019	2	-32	-20	-20	N/A
6/30/2019	3	-34	-11	-11	N/A
3/31/2019	3	-34	-11	-11	N/A
12/31/2018	3	-19	-15	-15	N/A
9/30/2018	3	-28	-17	-17	N/A
6/30/2018	3	-32	-17	-17	N/A
3/31/2018	3	-27	-18	-18	N/A
12/31/2017	3	-46	-16	-15	N/A
9/30/2017	3	-34	N/A	-15	N/A
6/30/2017	2	-23	N/A	-15	N/A
3/31/2017	2	-27	N/A	-14	N/A
12/31/2016	2	-18	N/A	-14	N/A
9/30/2016	2	-15	N/A	-15	N/A
6/30/2016	2	-16	N/A	-14	N/A
3/31/2016	2	-13	N/A	-16	N/A
12/31/2015	2	-15	N/A	-16	N/A
9/30/2015	2	-13	N/A	-15	N/A
6/30/2015	1	-15	N/A	-16	N/A
3/31/2015	1	-16	N/A	-15	N/A
12/31/2014	1	-17	N/A	-16	N/A
9/30/2014	1	-19	N/A	-18	N/A
6/30/2014	1	-22	N/A	-21	N/A
3/31/2014	1	-23	N/A	-28	N/A
12/31/2013	1	-30	N/A	-34	N/A
9/30/2013	1	-36	N/A	-38	N/A
6/30/2013	1	-41	N/A	-44	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DCTH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: DCTH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DCTH is expected to become profitable in the next 3 years.

Revenue vs Market: DCTH's revenue (41.5% per year) is forecast to grow faster than the US market (7.9% per year).

High Growth Revenue: DCTH's revenue (41.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if DCTH's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Delcath Systems Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Forecast breakeven date pushed back to 2026

No longer forecast to breakeven

Consensus revenue estimates fall by 34%

Consensus revenue estimates fall by 18%

Price target increased by 11% to US$18.20

Consensus EPS estimates upgraded to US$1.92 loss

Recent updates

Delcath Systems, Inc., Annual General Meeting, May 23, 2024

Forecast breakeven date pushed back to 2026

Delcath Systems, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Delcath Systems, Inc. Appoints Martha S. Rook as Chief Operating Officer

Delcath Systems, Inc. Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

Delcath Systems, Inc. Announces Executive Changes

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing Hepzato Kit™

Is Delcath Systems (NASDAQ:DCTH) Using Debt In A Risky Way?

No longer forecast to breakeven

CEO & Director recently bought US$100k worth of stock

Chief Medical Officer recently bought US$149k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 34%

Insufficient new directors

Delcath Systems (NASDAQ:DCTH) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates fall by 18%

Independent Chairman recently bought US$51k worth of stock

CEO & Director exercised options to buy US$171k worth of stock.

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

Price target increased by 11% to US$18.20

Consensus EPS estimates upgraded to US$1.92 loss

New major risk - Shareholder dilution

No longer forecast to breakeven

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Delcath Systems, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

Delcath Systems, Inc. Appoints Sandra Pennell as Senior Vice President of Finance

Delcath Systems, Inc. Provides Preliminary Earnings Guidance for the First Quarter Ended March 31, 2023

Consensus revenue estimates decrease by 46%, EPS upgraded

Full year 2022 earnings: EPS and revenues miss analyst expectations

Delcath Systems, Inc. Announces Board Changes

Delcath Systems, Inc. Announces New Drug Application Resubmission for HEPZATO Kit

Delcath Systems Announces Updated Results from Chopin Phase 1B Trial Published in Cardiovascular and Interventional Radiology

Forecast to breakeven in 2025

Independent Director recently bought US$55k worth of stock

Delcath Systems, Inc. announced that it has received $6.201779 million in funding

Delcath Systems, Inc. Announces Results of Single Center Study on Delcath's CHEMOSAT Hepatic Delivery System in the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$18.20

Delcath Systems, Inc. Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Results of A Multicenter Study on Delcath's Chemosat Hepatic Delivery System Published in Cardiovascular and Interventional Radiology

Delcath Systems Q2 2022 Earnings Preview

CEO & Director recently bought US$250k worth of stock

Delcath Systems, Inc. announced that it has received $4.999998 million in funding

Delcath Systems, Inc. announced that it expects to receive $5.000038 million in funding

Delcath Systems to raise $5M in stock and warrants offering

Delcath Systems: Revisiting A $5 Lottery Ticket

Price target decreased to US$21.20

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Price target decreased to US$22.00

Delcath Systems, Inc., Annual General Meeting, May 04, 2022

Consensus forecasts updated

Is Delcath Systems (NASDAQ:DCTH) Weighed On By Its Debt Load?

Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT

Delcath Systems, Inc. Appoints Anthony Dias as its New Vice President of Finance

Delcath Systems, Inc. Announces Result of Single Center Study on Delcath’s CHEMOSAT Hepatic Delivery System Published in Melanoma Research

CEO & Director recently bought US$200k worth of stock

Price target increased to US$23.50

Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis

Does Delcath Systems (NASDAQ:DCTH) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: US$0.94 loss per share (vs US$1.16 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.96 loss per share (vs US$1.91 loss in 2Q 2020)

Delcath Systems, Inc. announced that it expects to receive $20 million in funding from Avenue Capital Group

Diving Into Delcath Systems

CEO & Director recently bought US$149k worth of stock